China Shineway Pharmaceutical Group Limited (FRA:C1S)
Germany
· Delayed Price · Currency is EUR 0.7950
-0.0150 (-1.85%)
At close: May 9, 2025, 10:00 PM CET
FRA:C1S Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 3,778 | 4,517 | 3,951 | 3,224 | 2,656 | Upgrade
|
| Revenue Growth (YoY) | -16.35% | 14.32% | 22.55% | 21.38% | -1.86% | Upgrade
|
| Cost of Revenue | 946.29 | 1,122 | 1,012 | 813.21 | 667.86 | Upgrade
|
| Gross Profit | 2,832 | 3,394 | 2,938 | 2,410 | 1,988 | Upgrade
|
| Selling, General & Admin | 1,889 | 2,308 | 2,098 | 1,756 | 1,459 | Upgrade
|
| Research & Development | 100.52 | 110.46 | 117.45 | 112.71 | 99.71 | Upgrade
|
| Operating Expenses | 1,996 | 2,424 | 2,225 | 1,876 | 1,565 | Upgrade
|
| Operating Income | 835.99 | 970.1 | 713.58 | 534.37 | 422.4 | Upgrade
|
| Interest Expense | -6.13 | -2.74 | -0.63 | -1.25 | -16.6 | Upgrade
|
| Interest & Investment Income | 189.35 | 105.51 | 99.1 | 104.14 | 132.66 | Upgrade
|
| Currency Exchange Gain (Loss) | -55.44 | 6.61 | -8.52 | -2.9 | -1.95 | Upgrade
|
| Other Non Operating Income (Expenses) | 177.94 | 163.17 | 113.37 | 102.23 | 85.74 | Upgrade
|
| EBT Excluding Unusual Items | 1,142 | 1,243 | 916.9 | 736.58 | 622.25 | Upgrade
|
| Impairment of Goodwill | - | - | - | - | -56.79 | Upgrade
|
| Gain (Loss) on Sale of Assets | 4.01 | -2.39 | 0.13 | -16.47 | 2.06 | Upgrade
|
| Asset Writedown | - | - | - | - | -172.81 | Upgrade
|
| Other Unusual Items | - | - | - | - | 0.32 | Upgrade
|
| Pretax Income | 1,146 | 1,240 | 917.03 | 720.1 | 395.02 | Upgrade
|
| Income Tax Expense | 305.67 | 270.74 | 194.25 | 163.43 | 99.99 | Upgrade
|
| Earnings From Continuing Operations | 840.05 | 969.51 | 722.77 | 556.67 | 295.03 | Upgrade
|
| Net Income | 840.05 | 969.51 | 722.77 | 556.67 | 295.03 | Upgrade
|
| Net Income to Common | 840.05 | 969.51 | 722.77 | 556.67 | 295.03 | Upgrade
|
| Net Income Growth | -13.35% | 34.14% | 29.84% | 88.68% | -41.36% | Upgrade
|
| Shares Outstanding (Basic) | 755 | 755 | 755 | 755 | 757 | Upgrade
|
| Shares Outstanding (Diluted) | 755 | 755 | 755 | 755 | 757 | Upgrade
|
| Shares Change (YoY) | - | - | 0.03% | -0.21% | -3.10% | Upgrade
|
| EPS (Basic) | 1.11 | 1.28 | 0.96 | 0.74 | 0.39 | Upgrade
|
| EPS (Diluted) | 1.11 | 1.28 | 0.96 | 0.74 | 0.39 | Upgrade
|
| EPS Growth | -13.35% | 34.14% | 29.79% | 89.08% | -39.08% | Upgrade
|
| Free Cash Flow | 823.02 | 788.31 | 980.21 | 609.52 | 572.54 | Upgrade
|
| Free Cash Flow Per Share | 1.09 | 1.04 | 1.30 | 0.81 | 0.76 | Upgrade
|
| Dividend Per Share | 0.540 | 0.420 | 0.320 | 0.390 | 0.320 | Upgrade
|
| Dividend Growth | 28.57% | 31.25% | -17.95% | 21.88% | 39.13% | Upgrade
|
| Gross Margin | 74.95% | 75.15% | 74.38% | 74.77% | 74.85% | Upgrade
|
| Operating Margin | 22.13% | 21.48% | 18.06% | 16.58% | 15.90% | Upgrade
|
| Profit Margin | 22.23% | 21.47% | 18.30% | 17.27% | 11.11% | Upgrade
|
| Free Cash Flow Margin | 21.78% | 17.45% | 24.81% | 18.91% | 21.56% | Upgrade
|
| EBITDA | 891.44 | 1,019 | 888.23 | 705.11 | 621.85 | Upgrade
|
| EBITDA Margin | 23.59% | 22.56% | 22.48% | 21.87% | 23.42% | Upgrade
|
| D&A For EBITDA | 55.45 | 49.02 | 174.65 | 170.75 | 199.45 | Upgrade
|
| EBIT | 835.99 | 970.1 | 713.58 | 534.37 | 422.4 | Upgrade
|
| EBIT Margin | 22.13% | 21.48% | 18.06% | 16.58% | 15.90% | Upgrade
|
| Effective Tax Rate | 26.68% | 21.83% | 21.18% | 22.70% | 25.31% | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.